FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
The original release is unavailable here.
Earlier from Boston Scientific
- Boston Scientific enters into $2 billion accelerated share repurchase agreement
- Boston Scientific announces strategic investment in MiRus LLC
- FDA issues most serious recall for certain pacemaker devices by Boston Scientific
- Penumbra, Inc. Reports First Quarter 2026 Financial Results